Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Next Previous
X
Search
Trial Profile

A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varoglutamstat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SAPHIR 2
  • Sponsors Vivoryon Therapeutics

    • Most Recent Events

    • 29 Aug 2019 According to a Vivoryon Therapeutics AG media release, trial initiation is anticipated in the first quarter of 2020 with the topline results expected in the second half of 2022.
    • 19 Jul 2019 Status changed from planning to recruiting, according to a Vivoryon company website.
    • 29 Nov 2018 According to a Probiodrug media release, presented the detailed study design of the Phase 2b core program of PQ-912 which incorporated the newest FDA and EMA draft guidance for early AD trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top